“One of the unique aspects of our program is the requirement to write a clinical trial. This is an immensely helpful experience as there is no better way to learn the process than by actively going through the process. To be able to do this during fellowship is a great advantage.”
Angela Hirbe MD PhD, Fellowship Program Graduate 2016
Clinical research is an expectation of the fellowship program. During year 1, all fellows are expected to identify a mentor and to work with them to develop a clinical protocol. Mentors are a good source of potential ideas, a sense of feasibility, and guidance through a successful project. Engaging a research project provides important training and understanding into how new medical knowledge is acquired, how to critically read a clinical paper, and how to incorporate new approaches into practice. A thorough research experience is essential for fellows anticipating academic careers and is instrumental in teaching clinicians how to decipher the rapidly changing literature.
A “letter of intent” (LOI) represents a 1-2 page description of the rationale, broad study design, projected sample sizes, and statistics. Fellows are expected to complete an initial LOI by the beginning of 1st year winter, and they will present their concepts at the Spring and Fall research symposia as they evolve into clinical trials and completed projects.
Multiple resources are available to assist in the initial concept and LOI. Fellows are encouraged to meet regularly with their mentor to discuss concepts and details. A database of prior LOIs is available as examples. We have established a “Clinical Trial Bootcamp” that consists of lectures on LOI formatting, clinical trial designs, clinical trial statistics, navigating IRB submission, database utilization, and polishing your biosketch.
Current Fellow LOI Projects
|Second Year Fellows|
|Fellow||LOI Mentor||LOI Title|
|Zachary Crees||Stockerl-Goldstein, Uy, DiPersio||A Phase II Randomized, Double-Blind Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (auto-HCT) for Multiple Myeloma (MM)|
|Whitney Hensing||Ma, Bose||Neratinib and T-DM1 in HER2 mutated malignancies|
|Michael Iglesia||Park||A phase I biomarker-driven combination trial of rucaparib, nivolumab, and palliative radiotherapy in metastatic homologous recombination deficient gastroesophageal, pancreatic, and biliary tract carcinoma|
|David Russler-Germain||Uy||High-Dose Blinatumomab For Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia|
|Jing Xi||Campian, Ma||A phase II study of liposomal irinotecan in combination with pembrolizumab for triple-negative breast cancer with brain metastases|
|Alice Zhou||Ghobadi||Prospective study of Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS); imaging and biomarker correlates|
|Third Year Fellows|
|Fellow||LOI Mentor||LOI Title|
|Dhruv Bansal||Pachynski||A Phase 1b Clinical Trial of Cabozantinib and Abiraterone with Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer
|Ryan Day||Jacoby, Walter||Phase II Trial Evaluating CC-486 and Venetoclax in MDS Relapsed After Allogeneic Transplant|
|Vanessa Eulo||Van Tine||A Randomized Phase II trial of Cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma|
|Scott Goldsmith||Vij||A Phase I/II Study of Isatuximab, Bendamustine, and Prednisone in Penta-refractory Multiple Myeloma|
|Miriam Jacobs||Adkins||A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that Progressed or Recurred within Six Months after Platinum-based Chemotherapy|
|Mary-Kate Malecek||Mehta-Shah Bartlett||Phase I Study with Dose Expansion of Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma|
|Gradon Nielsen||Wildes||In-Home Sensor Monitoring of Older Adults with Cancer: A Pilot Study|
|Lauren Shea||Mehta-Shah||A phase I study with an expansion cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)|
|Fellow||LOI Mentor||LOI Title|
|Brett Herzog||Morgensztern||A Phase II Study of Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)|
|Ramon Jin||Park||Phase Ib/II Trial of DS-8201 in Combination with Copanlisib in HER2-positive Gastric Cancer|
Research is a central component of training at Washington University. Fellows are encouraged to publish interesting case reports as they find them, to complete retrospective studies, clinical trials, and basic science projects.
Second and third-year fellows are encouraged to apply for external research training opportunities in programs such as the ASH CRTI, the ASCO Vail Clinical Trials Workshop, or the ASBMT Clinical Research Training Course. One fellow per year may be sponsored in the Masters in Clinical Investigation Program at Washington University. Internal funding mechanisms are in place and often facilitate research during the third year that may extend into the initial years after fellowship. These include the R25 Cancer Genomics and Outcomes Research Program (STRENGTH), the K12 Paul Calabresi Career Development Award, the KL2 Program, and the T32 training program in molecular oncology. Fellows on the laboratory investigator track (including those in the Physician Scientist Training Pathway Program) may be appointed to the T32 training program in molecular hematology.
Fellows are encouraged to attend one national meeting per year and many fellows participate in meetings sponsored by the Alliance for Clinical Trial to understand how cooperative research projects are organized and completed.
Senior fellows are expected to present their research in subspecialty “work in progress” meetings and in Grand Rounds forums.
“There are lots of opportunities for finding mentors, who are world leaders in their respective fields, strong clinicians, and wonderful human beings.”
Siddhartha Devarakonda MBBS MD, Fellowship Program Graduate 2017
Career Development and Mentorship
Fellows are encouraged to explore diverse career options in Hematology/Oncology. Broad clinical exposure to major tumor types in oncology and to benign and malignant hematology is required. Diverse subspecialty clinics are available for training in the 2nd and 3rd years as fellows identify areas of interest. Broad opportunities exist for clinical, translational, and basic science research. Two co-chief fellow positions provide opportunities for administrative experience.
Fellows meet with the program directors twice a year to discuss progress, development, and future goals. These meetings provide critical feedback and opportunities to individualize the fellow’s training opportunities and make use of local and external resources.
Mentors play a key role in guiding fellow career development. Fellows are expected to identify a primary mentor during their first year, and then to identify additional mentors who form a career development committee. The primary mentor is expected to meet regularly with the fellow and help them develop their research program and career. Members of the career development committee meet with fellows twice a year, commonly organized around work in progress presentations. They provide a broader mentorship opportunity and an external review of research and career development.
Fellowship Program Productivity
Our fellows are well represented at local, national and international meetings and are competitive for grants and awards.
In Academic Year 2020 notable achievements include:
- 3 Fellows accepted to FDA/ASCO Fellows Day Workshop
- 2 Fellows accepted to ASCO/AACR Methods in Clinical Cancer Research Workshop
- 1 Fellow accepted to AACR Molecular Biology in Clinical Oncology Workshop
- 2 Fellows accepted to R25 STRENGTH program
- 2 Fellows awarded abstract merit awards
- 3 Fellows awarded funded grants: ASH RTAF, Emerson Collective Cancer Research Fund; BETRNet Developmental Research Program